We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma (I-PACE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04985825
Recruitment Status : Withdrawn (Business decision)
First Posted : August 2, 2021
Last Update Posted : September 13, 2022
Sponsor:
Collaborator:
ICON plc
Information provided by (Responsible Party):
Centessa Pharmaceuticals plc ( Pega-One S.A.S. )

Tracking Information
First Submitted Date  ICMJE July 20, 2021
First Posted Date  ICMJE August 2, 2021
Last Update Posted Date September 13, 2022
Actual Study Start Date  ICMJE December 16, 2021
Actual Primary Completion Date August 17, 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 30, 2021)
Overall Response Rate (ORR) assessed by the Independent Central Review Committee (ICRC) according to the Study Response Criteria [ Time Frame: Up to 24 months ]
Proportion of patients achieving Complete Response (CR) or Partial Response (PR) assessed by the ICRC according to the Study Response Criteria
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: January 27, 2022)
  • Disease Control Rate (DCR) assessed by the ICRC according to the Study Response Criteria [ Time Frame: Up to 24 months ]
    Proportion of patients achieving CR, PR or Stable Disease (SD) assessed by the ICRC according to the Study Response Criteria
  • ORR assessed by the investigator according to the Study Response Criteria [ Time Frame: Up to 24 months ]
    Proportion of patients achieving CR or PR assessed by the investigator according to the Study Response Criteria
  • DCR assessed by the investigator according to the Study Response Criteria [ Time Frame: Up to 24 months ]
    Proportion of patients achieving CR, PR or SD assessed by the investigator according to the Study Response Criteria
  • Progression-free Survival (PFS) assessed by the ICRC [ Time Frame: Up to 24 months ]
    Time from date of start of treatment to date of the first progression documented by the ICRC
  • Duration of Response (DoR) assessed by the ICRC [ Time Frame: Up to 24 months ]
    Time from date of first assessment of response (CR or PR) to date of the first progression documented by the ICRC
  • Duration of Stable Disease (DoSD) assessed by the ICRC [ Time Frame: Up to 24 months ]
    Time from date of first assessment of SD to date of the first progression documented by the ICRC
  • PFS assessed by the investigator [ Time Frame: Up to 24 months ]
    Time from date of start of treatment to date of the first progression documented by the investigator
  • DoR assessed by the investigator [ Time Frame: Up to 24 months ]
    Time from date of first assessment of response (CR or PR) to date of the first progression documented by the investigator
  • DoSD assessed by the investigator [ Time Frame: Up to 24 months ]
    Time from date of first assessment of SD to date of the first progression documented by the investigator
  • ORR assessed by the ICRC according to the immune Response Evaluation Criteria in Solid Tumors (iRECIST) [ Time Frame: Up to 24 months ]
    Proportion of patients achieving CR or PR assessed by the ICRC according to the iRECIST
  • ORR assessed by the investigator according to the iRECIST [ Time Frame: Up to 24 months ]
    Proportion of patients achieving CR or PR assessed by the investigator according to the iRECIST
  • DCR assessed by the ICRC according to the iRECIST [ Time Frame: Up to 24 months ]
    Proportion of patients achieving CR, PR or SD assessed by the ICRC according to the iRECIST
  • DCR assessed by the investigator according to the iRECIST [ Time Frame: Up to 24 months ]
    Proportion of patients achieving CR, PR or SD assessed by the investigator according to the iRECIST
  • PFS assessed by the ICRC according to the iRECIST [ Time Frame: Up to 24 months ]
    Time from date of start of treatment to date of the first iRECIST progression documented by the ICRC
  • PFS assessed by the investigator according to the iRECIST [ Time Frame: Up to 24 months ]
    Time from date of start of treatment to date of the first iRECIST progression documented by the investigator
  • DoR assessed by the ICRC according to the iRECIST [ Time Frame: Up to 24 months ]
    Time from date of first assessment of response (CR or PR) to date of the first iRECIST progression documented by the ICRC
  • DoR assessed by the investigator according to the iRECIST [ Time Frame: Up to 24 months ]
    Time from date of first assessment of response (CR or PR) to date of the first iRECIST progression documented by the investigator
  • DoSD assessed by the ICRC according to the iRECIST [ Time Frame: Up to 24 months ]
    Time from date of first assessment of SD to date of the first iRECIST progression documented by the ICRC
  • DoSD assessed by the investigator according to the iRECIST [ Time Frame: Up to 24 months ]
    Time from date of first assessment of SD to date of the first iRECIST progression documented by the investigator
  • Incidence of Adverse Events [ Time Frame: Up to 24 months ]
    Safety and tolerability profile assessed by Common Terminology Criteria for Adverse Events v5.0
  • Frequency of dose interruptions and reductions [ Time Frame: Up to 24 months ]
    Safety and tolerability profile assessed by frequency of dose interruptions and reductions
  • Duration of dose interruptions and reductions [ Time Frame: Up to 24 months ]
    Safety and tolerability profile assessed by duration of dose interruptions and reductions
  • Concentrations of imgatuzumab-reactive antibodies [ Time Frame: Up to 24 months ]
    Immunogenicity profile characterized by concentrations of imgatuzumab-reactive antibodies
  • Maximum observed concentration (C[max]) [ Time Frame: Up to 24 months ]
    Pharmacokinetic profile characterized by the maximum observed concentration (C[max]) of imgatuzumab
  • Area under the curve (AUC) [ Time Frame: Up to 24 months ]
    Pharmacokinetic profile characterized by the area under the curve (AUC) of imgatuzumab
  • Terminal half-life (t[1/2]) [ Time Frame: Up to 24 months ]
    Pharmacokinetic profile characterized by the terminal half-life (t[1/2]) of imgatuzumab
  • Time to maximum concentration (Tmax) [ Time Frame: Up to 24 months ]
    Pharmacokinetic profile characterized by the time to maximum concentration (Tmax) of imgatuzumab
  • Change in scores of patient-reported outcomes [ Time Frame: Up to 24 months ]
    Quality of life assessed by change in scores of patient-reported outcomes in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). Scores are transformed linearly to a zero to 100 scale. A higher score on the functional scale and the global Health related Quality of Life indicates better functioning
Original Secondary Outcome Measures  ICMJE
 (submitted: July 30, 2021)
  • Disease Control Rate (DCR) assessed by the ICRC according to the Study Response Criteria [ Time Frame: Up to 24 months ]
    Proportion of patients achieving CR, PR or Stable Disease (SD) assessed by the ICRC according to the Study Response Criteria
  • ORR assessed by the investigator according to the Study Response Criteria [ Time Frame: Up to 24 months ]
    Proportion of patients achieving CR or PR assessed by the investigator according to the Study Response Criteria
  • DCR assessed by the investigator according to the Study Response Criteria [ Time Frame: Up to 24 months ]
    Proportion of patients achieving CR, PR or SD assessed by the investigator according to the Study Response Criteria
  • Progression-free Survival (PFS) assessed by the ICRC [ Time Frame: Up to 24 months ]
    Time from date of start of treatment to date of the first progression documented by the ICRC
  • Duration of Response (DoR) assessed by the ICRC [ Time Frame: Up to 24 months ]
    Time from date of first assessment of response (CR or PR) to date of the first progression documented by the ICRC
  • Duration of Stable Disease (DoSD) assessed by the ICRC [ Time Frame: Up to 24 months ]
    Time from date of first assessment of SD to date of the first progression documented by the ICRC
  • PFS assessed by the investigator [ Time Frame: Up to 24 months ]
    Time from date of start of treatment to date of the first progression documented by the investigator
  • DoR assessed by the investigator [ Time Frame: Up to 24 months ]
    Time from date of first assessment of response (CR or PR) to date of the first progression documented by the investigator
  • DoSD assessed by the investigator [ Time Frame: Up to 24 months ]
    Time from date of first assessment of SD to date of the first progression documented by the investigator
  • ORR assessed by the ICRC according to the immune Response Evaluation Criteria in Solid Tumors (iRECIST) [ Time Frame: Up to 24 months ]
    Proportion of patients achieving CR or PR assessed by the ICRC according to the iRECIST
  • ORR assessed by the investigator according to the iRECIST [ Time Frame: Up to 24 months ]
    Proportion of patients achieving CR or PR assessed by the investigator according to the iRECIST
  • DCR assessed by the ICRC according to the iRECIST [ Time Frame: Up to 24 months ]
    Proportion of patients achieving CR, PR or SD assessed by the ICRC according to the iRECIST
  • DCR assessed by the investigator according to the iRECIST [ Time Frame: Up to 24 months ]
    Proportion of patients achieving CR, PR or SD assessed by the investigator according to the iRECIST
  • PFS assessed by the ICRC according to the iRECIST [ Time Frame: Up to 24 months ]
    Time from date of start of treatment to date of the first iRECIST progression documented by the ICRC
  • PFS assessed by the investigator according to the iRECIST [ Time Frame: Up to 24 months ]
    Time from date of start of treatment to date of the first iRECIST progression documented by the investigator
  • DoR assessed by the ICRC according to the iRECIST [ Time Frame: Up to 24 months ]
    Time from date of first assessment of response (CR or PR) to date of the first iRECIST progression documented by the ICRC
  • DoR assessed by the investigator according to the iRECIST [ Time Frame: Up to 24 months ]
    Time from date of first assessment of response (CR or PR) to date of the first iRECIST progression documented by the investigator
  • DoSD assessed by the ICRC according to the iRECIST [ Time Frame: Up to 24 months ]
    Time from date of first assessment of SD to date of the first iRECIST progression documented by the ICRC
  • DoSD assessed by the investigator according to the iRECIST [ Time Frame: Up to 24 months ]
    Time from date of first assessment of SD to date of the first iRECIST progression documented by the investigator
  • Incidence of Adverse Events [ Time Frame: Up to 24 months ]
    Safety and tolerability profile assessed by Common Terminology Criteria for Adverse Events v5.0
  • Frequency and duration of dose interruptions and reductions [ Time Frame: Up to 24 months ]
    Safety and tolerability profile assessed by frequency and duration of dose interruptions and reductions
  • Concentrations of imgatuzumab-reactive antibodies [ Time Frame: Up to 24 months ]
    Immunogenicity profile characterized by concentrations of imgatuzumab-reactive antibodies
  • Maximum observed concentration (C[max]) [ Time Frame: Up to 24 months ]
    Pharmacokinetic profile characterized by the maximum observed concentration (C[max]) of imgatuzumab
  • Area under the curve (AUC) [ Time Frame: Up to 24 months ]
    Pharmacokinetic profile characterized by the area under the curve (AUC) of imgatuzumab
  • Terminal half-life (t[1/2]) [ Time Frame: Up to 24 months ]
    Pharmacokinetic profile characterized by the terminal half-life (t[1/2]) of imgatuzumab
  • Time to maximum concentration (Tmax) [ Time Frame: Up to 24 months ]
    Pharmacokinetic profile characterized by the time to maximum concentration (Tmax) of imgatuzumab
  • Change in scores of patient-reported outcomes [ Time Frame: Up to 24 months ]
    Quality of life assessed by change in scores of patient-reported outcomes in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma
Official Title  ICMJE Phase 2 Study of Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma (I-PACE)
Brief Summary This study will evaluate the anti-tumor activity, safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of imgatuzumab, a monoclonal antibody against epidermal growth factor receptor (EGFR) with enhanced antibody-dependent cellular cytotoxicity (ADCC) in patients with advanced cutaneous squamous cell carcinoma (CSCC). Quality of life of patients treated with imgatuzumab will also be assessed.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Cutaneous Squamous Cell Carcinoma
Intervention  ICMJE Drug: Imgatuzumab
Imgatuzumab administered as an intravenous infusion on Day 1 and Day 8 of the first 21-day cycle, and on Day 1 of each subsequent 14-day cycle.
Study Arms  ICMJE Experimental: Imgatuzumab monotherapy
Intervention: Drug: Imgatuzumab
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Withdrawn
Actual Enrollment  ICMJE
 (submitted: September 12, 2022)
0
Original Estimated Enrollment  ICMJE
 (submitted: July 30, 2021)
87
Actual Study Completion Date  ICMJE August 17, 2022
Actual Primary Completion Date August 17, 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Key Inclusion Criteria:

  • Histologically confirmed diagnosis of CSCC
  • CSCC of advanced stage
  • Males or females at least 18 years of age at the time of consent
  • Signed informed consent provided prior to any study procedures
  • Ability to and willing to understand informed consent and comply with protocol requirements and procedures
  • No more than two prior lines of systemic treatment for advanced disease
  • Patients must have at least one lesion that is considered as measurable according to the Study Response Criteria
  • Eastern Cooperative Oncology Group performance status 0 or 1
  • Adequate function of bone marrow, liver, kidneys
  • Availability of tumor tissue sample (either an archival specimen or a fresh biopsy material) at Screening

Key Exclusion Criteria:

  • Prior systemic treatment for advanced disease with any anti-EGFR agent
  • Active central nervous system metastasis
  • Systemic anti-cancer therapy within five half-lives or two weeks, whichever is shorter, prior to first dose of the study drug
  • Persistent toxicities from previous systemic anti-neoplastic treatments
  • Wide-field radiotherapy within four weeks, or focal radiation for analgesic purpose or for lytic lesions at risk of fracture within two weeks prior to first dose of the study drug, or no recovery from side effects of such intervention
  • Major surgery within four weeks prior to first dose of the study drug, or no recovery from side effects of such intervention
  • Active infection requiring therapy
  • Concomitant use of systemic steroids at dose of >10 mg of prednisone or its equivalent per day
  • Known or suspected allergy/hypersensitivity to the study drug or any component of the study drug, other monoclonal antibodies, premedication medicines
  • Concurrent participation in another investigational therapeutic clinical trial
  • Pregnant or breast-feeding females
  • Mental or medical conditions that prevent the patient from giving informed consent or participating in the trial
  • Other severe acute or chronic medical or psychiatric conditions or laboratory abnormality that may increase the risk associated with the study participation or the study drug administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for enrollment in this study

Note: Other protocol defined Inclusion/Exclusion criteria apply.

Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Not Provided
Removed Location Countries Australia
 
Administrative Information
NCT Number  ICMJE NCT04985825
Other Study ID Numbers  ICMJE PO-001
2021-003262-12 ( EudraCT Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Current Responsible Party Centessa Pharmaceuticals plc ( Pega-One S.A.S. )
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Pega-One S.A.S.
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE ICON plc
Investigators  ICMJE
Study Director: Steffen Heeger, MD, PhD PegaOne S.A.S.
PRS Account Centessa Pharmaceuticals plc
Verification Date September 2022

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP